Skip to main content

Peer Review reports

From: Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer

Original Submission
7 Jul 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
1 Aug 2022 Reviewed Reviewer Report
3 Oct 2022 Reviewed Reviewer Report
16 Oct 2022 Author responded Author comments - Naoko Sueoka-Aragane
Resubmission - Version 3
16 Oct 2022 Submitted Manuscript version 3
18 Oct 2022 Author responded Author comments - Naoko Sueoka-Aragane
Resubmission - Version 4
18 Oct 2022 Submitted Manuscript version 4
21 Oct 2022 Author responded Author comments - Naoko Sueoka-Aragane
Resubmission - Version 5
21 Oct 2022 Submitted Manuscript version 5
Publishing
8 Dec 2022 Editorially accepted
23 Jan 2023 Article published 10.1186/s12885-022-10428-3

You can find further information about peer review here.

Back to article page